This title appears in the Scientific Report :
2010
Please use the identifier:
http://dx.doi.org/10.1007/s00259-009-1219-5 in citations.
Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme
Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme
We investigated the relationship between three-dimensional volumetric data of the metabolically active tumour volume assessed using [(11)C]-methionine positron emission tomography (MET-PET) and the area of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) enhancement assessed using magnetic re...
Saved in:
Personal Name(s): | Galldiks, N. |
---|---|
Ullrich, R. / Schroeter, M. / Fink, G. R. / Kracht, L.W. | |
Contributing Institute: |
Kognitive Neurowissenschaften; INM-3 |
Published in: | European Journal of Nuclear Medicine and Molecular Imaging, 37 (2010) S. 84 - 92 |
Imprint: |
Heidelberg [u.a.]
Springer-Verl.
2010
|
Physical Description: |
84 - 92 |
DOI: |
10.1007/s00259-009-1219-5 |
PubMed ID: |
19662410 |
Document Type: |
Journal Article |
Research Program: |
(Dys-)function and Plasticity Funktion und Dysfunktion des Nervensystems |
Series Title: |
European Journal of Nuclear Medicine and Molecular Imaging
37 |
Subject (ZB): | |
Publikationsportal JuSER |
We investigated the relationship between three-dimensional volumetric data of the metabolically active tumour volume assessed using [(11)C]-methionine positron emission tomography (MET-PET) and the area of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) enhancement assessed using magnetic resonance imaging (MRI) in patients with recurrent glioblastoma (GBM).MET-PET and contrast-enhanced MRI with Gd-DTPA were performed in 12 uniformly pretreated patients with recurrent GBM. To calculate the volumes in cubic centimetres, a threshold-based volume-of-interest (VOI) analysis of the metabolically active tumour volume (MET uptake indexes of > or = 1.3 and > or = 1.5) and of the area of Gd-DTPA enhancement was performed after coregistration of all images.In all patients, the metabolically active tumour volume as shown using a MET uptake index of > or = 1.3 was larger than the volume of Gd-DTPA enhancement (30.2 + or - 22.4 vs. 13.7 + or - 10.6 cm(3); p = 0.04). Metabolically active tumour volumes as shown using MET uptake indexes of > or =1.3 and > or = 1.5 and the volumes of Gd-DTPA enhancement showed a positive correlation (r = 0.76, p = 0.003, for an index of > or =1.3, and r = 0.74, p = 0.005, for an index of > or =1.5).The present data suggest that in patients with recurrent GBM the metabolically active tumour volume may be substantially underestimated by Gd-DTPA enhancement. The findings support the notion that complementary information derived from MET uptake and Gd-DTPA enhancement may be helpful in developing individualized, patient-tailored therapy strategies in patients with recurrent GBM. |